ReviewCancer cell international2025
The CCAT2 enigma: pioneering insights into colorectal cancer pathophysiology and therapeutic innovation.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing the LncRNA CCAT2 role in gastric cancer: from molecular insights to clinical implications.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a major global health burden and a leading cause of cancer-related morbidity and mortality. It ranks as the third most commonly diagnosed malignancy and the second leading cause of cancer-related deaths worldwide. These statistics underscore the urgent need for improved diagnostic, prognostic, and therapeutic strategies to combat the disease. The development of CRC is driven by a combination of genetic predisposition, environmental exposures, and lifestyle-related factors. Major risk factors include a family history of CRC, unhealthy diet, smoking, excessive alcohol consumption, and chronic intestinal inflammation. Effective CRC management relies heavily on early detection through colonoscopy, imaging modalities, and biomarker-based analyses. Standard treatment options include surgery, chemotherapy, radiotherapy, and targeted therapy, selected according to disease stage and patient condition. Emerging evidence identifies long non-coding RNAs (lncRNAs) as pivotal regulators of CRC progression, modulating gene expression and tumor biology. Among these, the lncRNA colon cancer-associated transcript 2 (CCAT2) has recently been recognized as a critical driver of CRC growth and metastasis. CCAT2 regulates gene expression and preserves chromosomal stability by modulating key oncogenic signaling pathways, including Wnt/β-catenin and MYC. Preliminary studies propose CCAT2 as a potential therapeutic target in CRC; however, further investigation is required to validate its feasibility, especially regarding delivery strategies and molecular specificity. This review provides a comprehensive overview of lncRNA CCAT2 in CRC development, emphasizing its underlying molecular mechanisms. It further discusses potential of CCAT2 as a diagnostic and prognostic biomarker, highlighting its relevance for future clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.